Stockscreener 앱 받기
110.16
2.83%
-3.21
시간 외 거래:
109.84
-0.32
-0.29%
Corcept Therapeutics Inc 주식(CORT)의 최신 뉴스
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains - Zacks Investment Research
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge - Zacks Investment Research
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Zacks Investment Research
Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case - Reuters
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
Corcept Therapeutics Inc (HTD.DU) Stock Forum & Discussion - Yahoo! Finance Canada
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR) - Supply Chain Digital
Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing - Yahoo Finance
Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com India
Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com Nigeria
Corcept Therapeutics president Sean Maduck sells $2.9 million in stock By Investing.com - Investing.com Australia
Corcept Therapeutics president Sean Maduck sells $2.9 million in stock - Investing.com
Corcept Therapeutics president sells $967k in shares - Investing.com
Corcept Therapeutics chief accounting officer sells $1.16m - Investing.com
Corcept Therapeutics Oncology President Reports Stock Option Exercise and Sales in Form 4 Filing - Kalkine Media
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercises and Sells Shares Under 10b5-1 Plan - Kalkine Media
100,000 stock options awarded to Corcept (CORT) officer vest over four years, subject to continued service. - Stock Titan
An officer reports 12,191 shares, including unvested awards, and four option positions at Corcept (CORT). - Stock Titan
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Zacks Investment Research
Corcept Therapeutics Incorporated (CORT) Stock Price, News, Quote & History - Yahoo! Finance Canada
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Yahoo Finance
Corcept Therapeutics Inc. R (HTD.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research
After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. - stocktitan.net
Non-controlling/minority interest of Corcept Therapeutics Incorporated. – HAN:HTD - TradingView
Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each - stocktitan.net
Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Nigeria
Corcept Therapeutics’ oncology president sells $29,842 in stock - Investing.com
Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Canada
Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History - Benzinga
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT) - Yahoo Finance
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant - TradingView
Corcept Therapeutics: Justin Gunn to Succeed Maduck, Assume New Responsibilities Starting Oct 1 >CORT - Moomoo
Corcept Announces Planned Leadership Transition - Business Wire
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus - finance.yahoo.com
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle - finance.yahoo.com
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - finance.yahoo.com
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Your Wyoming Link
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Zacks Investment Research
4.81%
0.07%
자본화:
|
볼륨(24시간):